Cancer Immunotherapy

This program seeks to make Dr. Convitu2019s breast cancer immunotherapy a standard low cost treatment option for patients. Through partnerships with research and health centers, JCWO works to advance its clinical trials in the US, South America and Europe using the ConvitVax. Additionally, this program looks to further enhance the anti-tumor effect of the ConvitVax by testing it in combination with other breast cancer therapies, as well as evaluate it as a treatment for other types of malignant solid tumors. With this program we direct our efforts to develop accessible immunotherapy protocols that can be affordable for underprivileged patients who lack the possibility of entering new innovative treatments.

We aim to make this immunotherapy available to patients who do not have access to new innovative therapies and in some cases, to standard of care treatments.

Every day we continue writing a new page, know our most outstanding milestones in Cancer Immunotherapy

2019

2019

2018

2018

2015

2015

2010

2010

2006

2006

2003

2003

2000

2000

1998

1998

1994

1994

1993

1993

1992

1992

1989

1989

1987

1987

1986

1986

1980

1980

1979

1979

1978

1978

1974

1974

1972

1972

1968

1968

1967

1967

1964

1964

1958

1958

1952

1952

1950

1950

2019

2019

FJC and JCWO publish a new article titled “Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment”.
2018

2018

Both organizations publish results of the study in a peer-reviewed journal with the title “Autologous tumor cells/bacillus Calmette-Guérin/formalin-based novel breast cancer vaccine induces an immune antitumor response”. The cancer immunotherapy (therapeutic vaccine) is registered with the name of ConvitVax. JCWO submits this project to the U.S. Food and Drug Administration (FDA) office as an Investigational New Drug (IND) application to obtain permission to advance into the clinical phase in Venezuela and receives approval in late 2018 to begin phase I clinical trials. The FJC and JCWO research team designed and executed the ConvitVax toxicity assay using 3 times the therapeutic dose in Balb/c mice.
2015

2015

The team of Fundación Jacinto Convit (FJC) publishes an article titled: “Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy” in a peer reviewed journal, Clinical & Translational Oncology. FJC and the Jacinto Convit World Organization (JCWO) design and execute a pre-clinical study in a murine model with induced breast tumors using 4T1 cells.
2010

2010

WHO recognizes doctor Jacinto Convit's treatment for leishmaniasis as part of the first generation of vaccines. Initiates the proposal of a pilot study to evaluate the efficacy of the cancer vaccine in patients with an advanced stage of the disease.
2006

2006

Submits a formal proposal of a personalized breast cancer immunotherapy (therapeutic vaccine) with the publication “Development of an auto-vaccine + BCG and its possible application in cancer treatments” in Venezuela’s national scientific journal, Gaceta Médica de Caracas. This immunotherapy uses autologous tumor cells in combination with BCG and low concentrations of formalin.
2003

2003

Doctor Convit and his team apply during 10 years the immunotherapy against leishmaniasis in Venezuela and observe a mean of 95.7% of cured patients with American Cutaneous Leishmaniasis. They publish an article with these results and based on this success, the immunotherapy is applied in other countries of the Latin American region to treat patients with LCL.
2000

2000

Doctor Convit becomes interested in cancer, concentrates on breast cancer. Identifies a diminished immunological response against the cancer cells and starts his first research studies on a proposed personalized immunotherapy against breast cancer.
1998

1998

WHO endorses the vaccine and the procedures applied by doctor Jacinto Convit and indicates that the work complies with the required parameters. They express its approval to continue with the tests carried out in Venezuela.
1994

1994

Doctor Convit together with seven laboratories worldwide carry out retrospective evaluations of the immunoprophylactic study and find that the vaccine reproduced by the WHO from the Wellcome Laboratory is substantially less active and with a lower antigenic content than the one used in Venezuela in previous studies. Conducts comparative studies between patients with leprosy treated with multidrug therapy, immunotherapy or the combination of both, show substantial early and persistent cell-mediated reactivity to M. leprae in many multibacillary patients treated with the combination.
1993

1993

Evaluates the clinical and immunological spectrum of LCL.
1992

1992

Publishes results on the evaluation of the vaccine used for an immunoprophylactic study, in which it is shown that there is no evidence in the first 5 years of follow-up that it offers significantly better protection against leprosy than BCG alone. The vaccine for this study was prepared by Wellcome Laboratories (UK) under a contract with the World Health Organization (WHO).
1989

1989

Uses the immunotherapy against American Cutaneous Leishmaniasis as a treatment for all localized, intermediate and diffuse forms of the disease.
1987

1987

Publishes the first comparative study between his leishmaniasis vaccine and the standard treatment for this disease.
1986

1986

Publishes the final description of the immunotherapy against leishmaniasis. Describes a highly effective immunotherapy (therapeutic vaccine) for localized cutaneous leishmaniasis (LCL). Doctor Convit and his team apply the immunotherapy against leprosy in Venezuela between 1979 and 1986 in 531 patients with this disease. The results show a significant clinical improvement, as well as an immune response with positive results.
1980

1980

Doctor Convit publishes the final description of the immunotherapy against leprosy.
1979

1979

Observes a clinical evidence of a favorable immune response when leprosy patients are inoculated with a mix of Mycobacterium leprae and BCG.
1978

1978

Defines the final prospect of a vaccine against leprosy and publishes his ideas and results.
1974

1974

 

Doctor Convit performs a successful culture of the mycobacteria in the armadillo and makes the final production of a specific immunotherapy (therapeutic vaccine) in combination with BCG to treat patients with leprosy.

Describes similarities between leprosy and leishmaniasis based on clinical, immunological, and pathological aspects.

1972

1972

Develops the Competency in Clearing Bacilli test (CCB test) and describes its correlation with the clinical aspects according to the immune response of the patient. Also, inoculates intradermal injections of the Mycobacterium leprae in combination with BCG, which activates the local immune response.
1968

1968

Performs the evaluation and identification of the immune response in patients with leishmaniasis.
1967

1967

Performs immunotherapy assays to induce the immune system and respond against the infecting bacteria.
1964

1964

Begins experimental research with the Mycobacterium leprae. Inoculates the bacteria in experimental animals to perform differentiation studies and identify the immune and cellular response.
1958

1958

Describes the clinical, immunological and parasitological aspects of leishmaniasis.
1952

1952

Observes the variation of the reaction to lepromin and tuberculin in leprosy patients after BCG vaccination.
1950

1950

Doctor Jacinto Convit begins testing several drugs and the use of the Bacillus Calmette-Guérin (BCG) to treat leprosy.

Take action and help us to continue to help others

Terms of Use          Privacy Policy